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Although CD4+ T cells are critical for orchestrat-
ing immunological processes, cancer immuno-
therapy has focused primarily on tumor-reactive 
CD8+ CTLs, largely because of their capacity to 
directly engage and kill transformed cells. Adop-
tive cellular therapy (ACT) using large numbers 
of tumor-reactive CD8+ CTLs expanded and dif-
ferentiated in vitro has shown significant clinical 
promise after lymphoablative conditioning, where 
responses occur in up to 70% of patients from 
whom tumor-reactive lymphocytes can be iso-
lated (Dudley et al., 2008; Muranski and Restifo, 
2009). Furthermore, the use of gene therapy to 
introduce  tumor-reactive  TCRs  in  autologous 
lymphocytes has been used as an option for those 
patients from whom tumor-reactive lymphocytes 
cannot be isolated (Morgan et al., 2006; Burns   
et  al.,  2009).  However,  these  strategies  are  all 
complicated by ex vivo manipulations and com-
plex mixtures of cytokines and growth factors   
required to prevent their terminal differentiation, 
and to allow them to maintain a pool of effector 
and memory tumor-reactive T cells after transfer 
in vivo (Gattinoni et al., 2005b, 2009).
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Adoptive transfer of large numbers of tumor-reactive CD8+ cytotoxic T lymphocytes  
(CTLs) expanded and differentiated in vitro has shown promising clinical activity against 
cancer. However, such protocols are complicated by extensive ex vivo manipulations of 
tumor-reactive cells and have largely focused on CD8+ CTLs, with much less emphasis on 
the role and contribution of CD4+ T cells. Using a mouse model of advanced melanoma, we 
found that transfer of small numbers of naive tumor-reactive CD4+ T cells into lymphope-
nic recipients induces substantial T cell expansion, differentiation, and regression of large 
established tumors without the need for in vitro manipulation. Surprisingly, CD4+ T cells 
developed cytotoxic activity, and tumor rejection was dependent on class II–restricted 
recognition of tumors by tumor-reactive CD4+ T cells. Furthermore, blockade of the co-
inhibitory receptor CTL-associated antigen 4 (CTLA-4) on the transferred CD4+ T cells re-
sulted in greater expansion of effector T cells, diminished accumulation of tumor-reactive 
regulatory T cells, and superior antitumor activity capable of inducing regression of spon-
taneous mouse melanoma. These findings suggest a novel potential therapeutic role for 
cytotoxic CD4+ T cells and CTLA-4 blockade in cancer immunotherapy, and demonstrate 
the potential advantages of differentiating tumor-reactive CD4+ cells in vivo over  
current protocols favoring in vitro expansion and differentiation.
© 2010 Quezada et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months   
it  is  available  under  a  Creative  Commons  License  (Attribution–Noncommer-
cial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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current approaches using differentiation and expansion in 
vitro. Finally, the data inform the rational development 
of combinatorial strategies incorporating CD4-ACT and 
CTLA-4 blockade to generate more potent and durable 
antitumor responses.
RESULTS
Transfer of small numbers of CD4+Trp1+ T cells  
in combination with radiation and CTLA-4 blockade produces 
potent rejection of established B16/BL6 melanoma tumors
To  determine  whether  activation  and  differentiation  of 
small numbers of naive tumor-reactive CD4+ T cells in vivo 
could drive rejection of established tumors, we used naive 
CD4+Trp1+  cells  isolated  from  Trp1  Tg  mice.  C57BL/6 
mice were challenged with a lethal dose (2.5 × 105 cells) of 
the poorly immunogenic B16/BL6 mouse melanoma line. 
10–12 d after challenge, when tumors were clearly visible 
(Fig. 1 b), mice received 5 Gy of irradiation (radiation ther-
apy [RT]) followed by adoptive transfer of naive CD4+Trp1+ 
cells  (CD4-ACT).  To  assess  the  potential  combinatorial   
efficacy of CTLA-4 blockade and CD4-ACT, a cohort of 
mice also received anti–CTLA-4 mAb. RT by itself failed to 
induce regression of established tumors (Fig. 1 a). Additional 
controls including anti–CTLA-4 + RT or anti–CTLA-4 + 
CD4+Trp1+  also  failed  to  induce  regression  (unpublished 
data). Remarkably, transfer of as few as 50,000 CD4+Trp1+ 
T cells into irradiated hosts was sufficient to induce initial 
regression of large established melanoma tumors and depig-
mentation in all mice (Fig. 1 a). However, in the absence of 
anti–CTLA-4, the combination of RT and CD4-ACT failed 
to eradicate tumors completely, and tumors recrudesced in 
up to 60% of mice (Fig. 1 a). The addition of anti–CTLA-4   
produced long-term protection in all mice (Fig. 1 a), as well 
as development of disseminated depigmentation (Fig. 1 b,   
far right). Analysis of T cell dynamics in the blood of treated 
mice showed rapid expansion of CD4+Trp1+ cells after   
transfer into irradiated mice (Fig. 1 c). CTLA-4 blockade   
increased expansion by two- to threefold, reaching up to 40% 
of blood lymphocytes (Fig. 1 c), while simultaneously prevent-
ing the expansion and accumulation of CD4+Trp1+Foxp3+ 
cells (Fig. 1 d).
Although mice receiving RT monotherapy showed 
no changes in serum levels of IFN- (Fig. 1 e) and TNF 
(Fig. 1 f), both inflammatory cytokines were increased 
significantly after CD4-ACT in irradiated hosts (Fig. 1,   
e and f). Cytokine production was markedly increased 
after CTLA-4 blockade (Fig. 1, e and f), correlating with 
the increase in CD4+Trp1+ cells (Fig. 1 c) and height-
ened tumor rejection (Fig. 1 a). These data demonstrate 
that adoptive transfer of small numbers of naive tumor-
reactive  CD4+  T  cells  into  irradiated  recipients  can   
mediate potent rejection of established melanoma. Incorpo-
ration of CTLA-4 blockade significantly enhanced T cell 
expansion, cytokine secretion, and antitumor activity, con-
ferring complete rejection and durable protection in all 
treated mice.
Although the role of CD4+ Th cells in enhancing and 
sustaining CD8+ T cell responses is well established (Pardoll 
and Topalian, 1998; Antony et al., 2005), recent evidence 
suggests more direct roles, lending support to the use of 
tumor-reactive  CD4+  T  cells  for  cancer  immunotherapy 
(Mumberg et al., 1999; Corthay et al., 2005; Perez-Diez   
et al., 2007). After expansion, in vitro, Th17-polarized   
tumor-reactive CD4+ cells are capable of rejecting established 
melanoma (Muranski et al., 2008). Furthermore, adoptive 
transfer of a large number of CD4+ T cells expanded from   
a single tumor-reactive T cell clone resulted in a complete 
response lasting 2 yr in a melanoma patient (Hunder et al., 
2008), although the precise cellular mechanisms regulating 
and driving tumor rejection remain unclear. Despite these 
encouraging data, incorporation of CD4+ T cells into ACT 
protocols remains challenging because of technical difficul-
ties in acquiring and expanding helper cells to the num-
bers thought necessary for ACT (Muranski and Restifo, 
2009). Interestingly, a growing body of evidence supports 
the idea that activation and differentiation of small numbers 
of adoptively transferred antigen-specific T cells in vivo can 
result  in  efficacious  long-lived  immunity  (Hataye  et  al., 
2006; Blair and Lefrançois, 2007), and that these responses 
can be further enhanced by host conditioning (Gonzalez 
et al., 2002; Rizzuto et al., 2009). Similar strategies could 
greatly affect ACT, perhaps circumventing the problems 
associated with priming, expansion, and differentiation of 
tumor-reactive CD4+ T cells in vitro. A greater under-
standing of the role of CD4+ T cells and of the mechanisms 
regulating their function in adoptive cancer immunother-
apy may therefore inform and enhance the development of 
these approaches.
We used a CD4+ TCR transgenic (Tg) mouse specific 
for  a  melanoma  differentiation  antigen  (tyrosinase-related 
protein 1 [Trp1]) as a model for the study of self-/tumor-
reactive CD4+ T cells during cancer immunotherapy (Muranski 
et al., 2008). We demonstrate that transfer of very small 
numbers of naive tumor-/self-reactive CD4+Trp1+ cells 
into irradiated recipients is followed by marked expansion 
and, most importantly, differentiation into cytotoxic CD4+ 
T cells, which efficiently eliminated established melanoma 
tumors in a mouse model of advanced disease. Furthermore, 
combination of this CD4-ACT protocol with blockade of 
the coinhibitory receptor CTL-associated antigen 4 (CTLA-4) 
on T cells resulted in increased expansion of effector T (Teff) 
cells, reduced numbers of T reg cells, higher IFN- levels, 
heightened in vivo cytotoxicity, and improved antitumor 
activity. Additional experiments testing the efficacy of this 
novel  combinatorial  approach  demonstrated  regression  of 
large melanoma lesions in a mouse model of autochthonous 
spontaneous melanoma, underlining the potential significance 
of our findings.
These results highlight the relevance of the CD4+ T cell 
compartment, and particularly of cytotoxic CD4+ T cells, 
in cancer immunotherapy, while providing evidence that 
T cell differentiation in vivo may afford advantages over JEM VOL. 207, March 15, 2010 
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IFN-, TNF, and IL-2, in vivo activation of tumor-reactive 
CD4+Trp1+ T cell also resulted in their differentiation into 
granzyme B–producing CD4+ T cells in both the periphery 
and in tumors (Figs. S1 and S2).
Analysis of tumor-infiltrating CD4+Trp1+ T cells also 
highlighted the importance of RT for T cell accumula-
tion (Fig. 2 d) and differentiation (Fig. 2 f and Fig. S2).   
Although CTLA-4 blockade failed to further increase the 
absolute number of intratumoral CD4+Trp1+ Teff cells in 
irradiated recipients, it markedly reduced the number of 
tumor-infiltrating CD4+Trp1+Foxp3+ T reg cells, mirror-
ing changes in the LNs and blood. The intratumor ratio of 
Trp1+  Teff  cells  to  Trp1+  T  reg  cells  (Fig.  2  g)  and  of 
CD4+Trp1+ Teff cells to total T reg cells (Fig. 2 h) increased 
several fold upon CTLA-4 blockade. Finally, histological 
analysis of T cell infiltrates confirmed lack of infiltration after 
monotherapy with RT or CD4-ACT, whereas their combi-
nation  significantly  enhanced  CD4+Trp1+  accumulation 
within tumors (Fig. 2 I; and Figs. S3 and S4). These data are 
consistent with those obtained from blood and support a role 
Combination of CD4+Trp1+ ACT and CTLA-4 blockade 
enhances activation and differentiation of effector 
CD4+Trp1+ T cells, and reduces the number of T reg cells
To further characterize the antitumor response induced by 
CD4+Trp1+ T cells, we analyzed their expansion, differentia-
tion,  and  function  in  LNs  and  tumors  8  d  after  transfer. 
CD4+Trp1+ Teff cells (Foxp3) were detectable in low num-
bers in LNs of nonirradiated recipients, increasing in number 
when transferred after RT (Fig. 2 a). CTLA-4 blockade   
significantly  increased  expansion  of  CD4+Trp1+  Teff  cells 
transferred into irradiated hosts (Fig. 2 a), while preventing 
expansion of CD4+Trp1+Foxp3+ T reg cells (Fig. 2 b). The 
combination of RT and CD4-ACT resulted in a marked 
Th1-like phenotype, with CD4+Trp1+ T cells secreting   
copious amounts of IFN-, TNF, and IL-2. (Fig. 2 c and 
Fig. S1). Contrary to its effect on the absolute number of 
CD4+Trp1+ Teff and T reg cells, CTLA-4 blockade had no 
impact on the frequency of IL-2, IFN-, or TNF single, 
double, or triple producers in LNs (Fig. 2 c and Fig. S1) or 
tumors (Fig. 2 f and Fig. S2). Remarkably, in addition to 
Figure 1.  Transfer of small numbers of CD4+Trp1+ T cells in combination with radiation and CTLA-4 blockade produces potent rejection  
of established B16/BL6 melanoma tumors. Tumor-bearing mice were treated at day 10 with 5 Gy of RT and were injected or not with 50,000 naive 
tumor-reactive CD4+Trp1+ cells and anti–CTLA-4. (a) Data are presented as tumor growth in each mouse (three left panels; representative of at least three 
independent experiments; n = 5 mice per group) and cumulative survival from two independent experiments (far right panel; n = 10 mice per group).  
(b) Representative images of tumors in mice treated with 5 Gy of RT and CD4+Trp1+ cells in the absence (top) or presence (bottom) of anti–CTLA-4. The  
far right panel shows disseminated depigmentation in mice surviving therapy. (c–f) Blood samples from mice treated with 5 Gy of RT (black line), 5 Gy + 
CD4+Trp1+ (red line), and 5 Gy + CD4+Trp1+ + anti–CTLA-4 (blue line) were monitored at different time points after tumor challenge. Data are representa-
tive of three independent experiments (n = 5 mice per group). c shows the percentage of CD4+Trp1+ T cells from blood lymphocytes, whereas d depicts 
the percentage of Foxp3+ cells within the CD4+Trp1+ population. Serum samples were analyzed over time and tested for levels of IFN- (e) and TNF (f). 
Error bars represent means ± SD.640 Tumor rejection by cytotoxic CD4+ T cells | Quezada et al.
driving further expansion of such cells while preventing   
T reg cell accumulation.
for  RT  in  the  activation  and  differentiation  of  tumor-
  reactive CD4+Trp1+ Teff cells and for CTLA-4 blockade in 
Figure 2.  Combination of CD4+Trp1+ ACT and CTLA-4 blockade enhances activation and differentiation of CD4+Trp1+ Teff cells and  
reduces the number of T reg cells. (a–e) Tumor-bearing mice were treated at day 10 with or without 5 Gy of RT followed by transfer of 50,000 
CD4+Trp1+ cells in the presence or absence of anti–CTLA-4 mAb. 8 d after therapy (day 18 after tumor challenge), mice were euthanized and numbers of 
CD4+Trp1+Foxp3 cells (Teff cells; a and d) and CD4+Trp1+Foxp3+ cells (T reg cells; b and e) were analyzed in LNs (a and b) and tumors (d and e). Numbers 
of CD4+Trp1+ Teff and T reg cells in tumors (d and e) were calculated as described in Materials and methods. (g and h) Proportions of CD4+Trp1+ Teff cells to 
CD4+Trp1+ T reg cells (g) and CD4+Trp1+ Teff cells to total T reg cells (h) were also calculated from tumor samples. CD4+Trp1+ cells from LNs (c) and tumor 
samples (f) were restimulated ex vivo, and IFN-, TNF, and IL-2 secretion was determined on a per cell basis. (i) In a parallel experiment, tumors were dis-
sected and fresh frozen in optimum cutting temperature solution, cut, and stained for DAPI (blue), CD31 (red), and CD4 (green). Samples were analyzed by 
confocal microscopy with a 20X water immersion objective. Bars, 50 µm. Images showing whole-tumor immunofluorescence are shown in Fig. S3. Data 
are representative of three independent experiments (n = 3 mice per group). Horizontal bars represent means.JEM VOL. 207, March 15, 2010 
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recipients were capable of rejecting established melanoma   
after triple therapy (Fig. 3 b). Tumors were also rejected   
in perforin/ (PFN/) recipient mice treated with triple ther-
apy, suggesting that rejection is independent of endogenous 
PFN-dependent killing activity (i.e., mediated by CD8 and 
NK cells). This was further confirmed by depletion experiments 
with anti-CD8 and anti-NK1.1 mAbs, which failed to prevent 
tumor rejection (unpublished data). Finally, to determine   
the cellular targets of anti–CTLA-4, we used recipient mice   
expressing human CTLA-4 instead of mouse CTLA-4 (Peggs   
et al., 2009). In these mice, anti–mouse CTLA-4 mAbs block 
CTLA-4 only on the transferred CD4+Trp1+ cells. As shown 
previously (Fig. 1 a), RT and CD4-ACT resulted in partial   
rejection in wild-type mice, whereas incorporation of anti–
mouse CTLA-4 resulted in complete tumor rejection (Fig. 3 c). 
Similar results were obtained when using human CTLA-4   
mice as recipients, suggesting that CTLA-4 blockade on   
only the transferred cells is sufficient to mediate complete pro-
tection (Fig. 3 d). Collectively, the data support a direct role   
for the transferred CD4+Trp1+ T cells in tumor rejection,   
mediated most likely through the action of IFN-. This activity 
is independent of endogenous CD4, CD8, and B cells, or NK 
cells, suggesting a direct effect of the transferred CD4+Trp1+ 
cells on the tumor.
Rejection of established tumors depends on IFN- secretion 
by CD4+Trp1+ T cells and is independent of TNF  
and endogenous T, B, and NK cells
To determine whether IFN- and TNF were directly in-
volved in tumor rejection, we used both neutralizing anti-
bodies and a variety of knockout mice as tumor recipients. 
TNF blockade during treatment with RT, CD4-ACT, and 
CTLA-4 blockade (triple therapy) had no impact on tumor 
rejection (Fig. 3 a). In contrast, neutralization of IFN-  
prevented rejection in four out of five mice, suggesting an 
important  mechanistic  role  for  IFN-  in  tumor  rejection 
(Fig. 3 a). Complete tumor eradication was observed after 
triple therapy using IFN-/ recipient mice, indicating that 
IFN- secreted by the transferred CD4+Trp1+ cells, and not 
by the host cells, is critical for antitumor activity (Fig. 3 a). 
IFN-R/ mice also rejected established tumors after triple 
therapy, suggesting that the target cell for IFN- could (at 
least in an initial phase) be the tumor itself (Fig. 3 a). How-
ever,  all  IFN-R/  recipients  regrew  pigmented  tumors 
40–70 d after the primary challenge, suggesting that IFN-–
sensitive cells other than the tumor are potentially important 
for complete tumor eradication.
Remarkably, tumor rejection appeared to be independent 
of endogenous CD4, CD8, and B cells because RAG/  
Figure 3.  Rejection of established tumors depends on IFN- secretion by CD4+Trp1+ T cells and is independent of TNF and endogenous T, B, 
and NK cells. Tumor-bearing mice were irradiated at day 10 with 5 Gy followed or not by treatment with 50,000 CD4+Trp1+ cells and anti–CTLA-4 mAb. 
Tumor growth was measured and data are presented for each independent mouse. (a) Mice received only 5 Gy (left) or 5 Gy + CD4+Trp1+ + anti–CTLA-4 
with control antibody or with neutralizing anti-TNF or anti–IFN- antibody. Two further groups included IFN-/ and IFN-R/ recipients treated at 
day 10 with 5 Gy, 50,000 CD4+Trp1+ cells, and anti–CTLA-4. (b) In a separate experiment, recipient PFN/ and Rag/ mice were compared with wild-type 
mice for their capacity to reject established melanoma after treatment at day 10 with 5 Gy, 50,000 CD4+Trp1+ cells, and anti–CTLA-4. (c and d) Mean  
tumor growth in mice treated with 5 Gy of RT + CD4+Trp1+ cells in the presence (blue line) or absence (red line) of anti–CTLA-4. Mice used for this set  
of experiments were either wild-type C57BL/6 (c) or CTLA-4 human Tg (d) mice in which anti–CTLA-4 antibodies will only block CTLA-4 on the transferred 
CD4+Trp1+ cells. Data are representative of at least two independent experiments (n = 5 mice per group).642 Tumor rejection by cytotoxic CD4+ T cells | Quezada et al.
targets (Fig. 5, c and e). Importantly, although killing activ-
ity  was  largely  inhibited  by  antibodies  blocking  class  II, 
blockade  of  FAS–FASL  interactions  did  not  significantly 
impair lysis of B cell targets or tumor cell targets (Fig. 5, d 
and e). Additional experiments blocking either FASL (MFL4 
clone) or TRAIL (N2B2 clone) in vivo also failed to pre-
vent tumor rejection in mice treated with triple therapy 
(unpublished data). In contrast, and in keeping with the 
high  levels  of  granzyme  B  expressed  by  tumor-reactive 
CD4+Trp1+ cells (Figs. S1 and S2), simultaneous blockade 
of  granzyme  B  and  PFN  activity  in  vitro  synergized  to   
prevent lysis of tumor targets (Fig. 5 f). Collectively, these 
data suggest that the cytolytic activity acquired by tumor-
reactive CD4+Trp1+ T cells depends on direct recognition 
of target cells through class II and degranulation of gran-
zyme-containing lytic granules.
Direct  recognition  and  specific  destruction  of  tumor   
targets in vitro suggests a requirement for class II expression 
by the target cells in vivo. To test whether B16/BL6 could 
express class II in vivo, we challenged mice with a traceable 
Thy1.1-expressing B16/BL6 melanoma cell line and quanti-
fied class II expression on Thy1.1-positive cells after therapy 
(Fig. 6, a and b). Class II was not detected on the Thy1.1-
  expressing tumor cells in the untreated group or on tumors 
from mice treated only with CD4+Trp1+ and anti–CTLA-4 
(Fig. 6, a and b). In contrast, high levels of class II could   
be found on tumor cells after triple therapy. Furthermore,   
although RT alone failed to induce class II up-regulation,   
the combination of RT and CD4+Trp1+ was as efficient as 
triple therapy at inducing class II up-regulation on tumor 
cells (not depicted).
A possible explanation for the high levels of class II ex-
pression could be the copious amounts of IFN- produced 
by tumor-reactive CD4+Trp1+, as IFN- has been shown to 
up-regulate expression of MHC molecules in several differ-
ent cell types (Boehm et al., 1997; Boss, 1997). In support of 
this mechanism, IFN- was absolutely necessary for class II 
up-regulation, which was completely ablated by administra-
tion of neutralizing antibodies (Fig. 6, a and b).
Finally, to test the direct class II dependence of in vivo 
recognition and rejection of melanoma tumors, we adop-
tively transferred CD4+Trp1+ T cells that had been primed in 
vivo into tumor-bearing class II knockout (CII/) recipi-
ents. Activated cells were used because of a preliminary ob-
servation that class II expression on recipient cells is required 
for priming of tumor-reactive CD4+ T cells, as transfer of 
naive CD4+Trp1+ T cells into irradiated CII/ mice failed 
to eradicate established tumors (unpublished data). Transfer 
of activated CD4+Trp1+ T cells into irradiated CII/ mice 
followed by CTLA-4 blockade resulted in complete tumor 
eradication. Notably, tumor rejection was completely ablated 
by antibodies blocking class II MHC (Fig. 6 c). Collectively, 
the data support a model in which IFN- secreted by activated 
CD4+Trp1+ T cells induces class II up-regulation on tumor 
cells, converting them into targets for cytotoxic CD4+Trp1+  
T cells.
Antitumor activity after CD4+Trp1+ T cell transfer is specific 
to B16/BL6 melanoma and does not prevent growth  
of an unrelated tumor
To determine whether the antitumor activity was tumor spe-
cific and not mediated through nonspecific mechanisms (i.e., 
activation of other cellular subsets such as inflammatory my-
eloid-derived cells; Mumberg et al., 1999; Corthay et al., 
2005),  we  challenged  mice  with  B16/BL6  melanoma  in   
one  flank  and  EL-4  lymphoma  in  the  contralateral  flank. 
Without  CD4+Trp1+  transfer,  both  EL-4  and  B16/BL6   
tumors continued to grow (Fig. 4 a), whereas triple therapy 
resulted in complete rejection of B16/BL6 melanoma with-
out influencing the growth of the unrelated EL-4 tumor   
(Fig. 4 b). To exclude the possibility that the inflammatory 
milieu  created  after  triple  therapy  induces  local  rejection   
of tumors regardless of specific recognition by CD4+Trp1+ 
cells, we injected a mixture of B16/BL6 and EL-4 in the 
same site and followed tumor progression after therapy. Tri-
ple therapy did not result in rejection of the tumor mixture 
(Fig. 4 c), arguing against bystander tumor rejection. In   
the absence of CD4+Trp1+ transfer, the tumor contained a 
mixture of B16/BL6 melanoma and EL-4 (black tumors), 
whereas after CD4+Trp1+ T cell transfer there was no detect-
able melanoma within the growing tumor (off-white tumors; 
Fig. 4 d). To further verify that B16/BL6 melanoma was be-
ing rejected in the coinjection setting, mice were challenged 
with a mixture of EL-4 and B16/BL6-luciferase and treated 
at day 10 with triple therapy. The luciferase signal was com-
pletely eliminated in the triple therapy group but not in con-
trol mice lacking CD4-ACT (Fig. 4, e and f). The data argue 
against a nonspecific or bystander mechanism of tumor   
rejection and, together with the tumor rejection data in   
IFN-R/ mice, suggest a direct impact of transferred 
CD4+Trp1+ T cells and IFN- on melanoma cells.
Tumor-reactive CD4+Trp1+ T cells develop  
class II–dependent killing activity
To determine if the antitumor responses achieved after triple 
therapy were caused by acquired cytotoxic activity and direct 
tumor killing by CD4+Trp1+ T cells, we performed a series 
of in vivo and in vitro killing experiments. Mice were chal-
lenged with tumors and treated at day 10 with or without 
RT, CD4+Trp1+ T cells, and anti–CTLA-4. CFSE-labeled 
B cell targets were injected i.v. 17 d after tumor challenge, 
and in vivo killing activity was determined 14–16 h later by 
quantification of the CFSEhigh peak (corresponding to target 
cells loaded with the class II–restricted peptide recognized by 
CD4+Trp1+ cells) relative to the unloaded CFSElow peak. 
CD4+Trp1+ cells acquired potent in vivo killing activity after 
transfer into irradiated recipients (Fig. 5 a). This activity was 
significantly enhanced after CTLA-4 blockade, whereas little 
to no activity was detected with CD4-ACT or RT alone 
(Fig. 5 a, right). Killing activity was confirmed in vitro, where 
CD4+Trp1+ cells isolated from triple therapy–treated mice 
and expanded in vitro were extremely efficient at eliminating 
peptide-loaded B cell targets (Fig. 5, b and d) or B16/BL6 JEM VOL. 207, March 15, 2010 
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pinnae of the ear between 4 and 6 mo of age (Pollock et al., 
2003). Mice received triple therapy after development of 
large melanoma lesions between 10 and 13 mo of age.   
Although untreated tumors never regress spontaneously in 
this model (Pollock et al., 2003), a remarkable regression of   
tumors in the ears, eyes, and tails was observed after triple 
therapy (Fig. 7, a and b). CD4+Trp1+ cells expanded greatly 
after transfer into irradiated mice (Fig. 7 d), as observed in the 
Triple therapy mediates tumor regression in a mouse model 
of spontaneous melanoma
To test the efficacy of this new combinatorial therapy in a 
stringent and more realistic model, we applied our treatment 
regimen to a mouse model of spontaneous melanoma. Gluta-
mate receptor 1 (Grm-1) Tg mice overexpress the metabo-
tropic Grm-1 driven by the melanocyte-specific promoter of 
dopachrome tautomerase and develop tumors in the tail and 
Figure 4.  Antitumor activity after CD4+Trp1+ T cell transfer is specific to B16/BL6 melanoma and does not prevent growth of an unrelated 
tumor. (a–e) Mice were challenged with B16/BL6 melanoma and EL-4 in opposing flanks (a and b) or coinjected in the same flank (c–e). 10 d after  
tumor challenge, all mice received 5 Gy of RT and anti–CTLA-4 mAb. Half of the mice were also treated with 50,000 CD4+Trp1+ T cells and all mice were 
monitored for tumor growth (a–c). (d) Representative images of mice challenged with B16/BL6 and EL-4 in the same site shows the growth of a pigmented 
tumor in the absence of CD4+Trp1+ transfer and growth of a nonpigmented tumor after administration of 50,000 tumor-reactive CD4+Trp1+ T cells Data 
are representative of three independent experiments (n = 5 mice per group). To verify that B16/BL6 melanoma is rejected in the coinjection setting, mice 
were challenged with EL-4 and B16/BL6-luciferase in the same site, and light emission was determined over time after tumor challenge and triple ther-
apy. (e) Representative images of luciferase signal disappearing from the tumor after therapy. (f) Quantification of luciferase signal and tumor growth. 
Data are representative of two independent experiments (n = 5 mice per group). Error bars represent means ± SD.644 Tumor rejection by cytotoxic CD4+ T cells | Quezada et al.
gest that the efficacy of this therapeutic regimen is not limited 
to transplantable tumor models but is also evident in a more 
stringent  model  of  spontaneous  and  disseminated  disease, 
which is thought to better represent human malignancies.   
transplantable B16/BL6 melanoma model (Fig. 1 c). High 
levels of IFN- and TNF were also detected in the blood of 
treated mice, occurring with a faster kinetic than with the 
transplantable melanoma line (Fig. 7, e and f). The data sug-
Figure 5.  Tumor-reactive CD4+Trp1+ T cells develop class II–dependent killing activity. (a) 10 d after tumor challenge, tumor-bearing mice were 
treated or not with 5 Gy of RT, 50,000 CD4+Trp1+ cells, 5 Gy + CD4+Trp1+, or 5 Gy + CD4+Trp1+ + anti–CTLA-4 mAb. 7 d after therapy (day 17 after tumor 
challenge), all mice were injected with CFSE-labeled B cell targets. CFSEhigh (5 µM) cells were also loaded with the class II–restricted peptide recognized by 
CD4+Trp1+ cells, whereas CFSElow (0.5 µM) cells were used as a control population. 14–16 h after i.v. injection of CFSE targets, mice were sacrificed and in 
vivo killing activity was quantified in single-cell suspensions from the spleens of each mouse. Data are representative of three independent experiments  
(n = 3 mice per group). Horizontal bars represent means. (b–f) CD4+Trp1+ T cells were primed in vivo and expanded in vitro to allow analysis of their in vitro 
killing activity. Tumor-reactive in vivo–primed CD4+Trp1+ T cells were incubated at different ratios with CFSE-loaded spleen targets (b and d) or B16/BL6 and 
EL-4 tumor targets (c, e, and f). (b and d) CFSElow B cell targets were also loaded with the class II–restricted peptide recognized by Trp1 cells, whereas CFSEhigh 
cells were used as the control population. (c, e, and f) B16/BL6 cells were loaded with 0.5 µM CFSE, whereas EL-4 control tumor cells were loaded with  
5 µM CFSE. Blocking anti–class II or anti-FASL antibodies were used at a final concentration of 50 µg/ml for all in vitro experiments (b–e). (f) In vitro killing 
of tumor targets was also tested in presence of 0.5 µM concanamycin A (PFN inhibitor) and/or 25 µM Z-AAD-CMK. In vitro killing activity was determined  
12–14 h after initiation of the assay by quantifying the decrease of the target population in comparison to the control population, as described in Materials 
and methods. Data are representative of four independent experiments. Numbers in a–c indicate percentages. Error bars in d–f represent means ± SD.JEM VOL. 207, March 15, 2010 
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informing a potential strategy for future clinical studies. Finally, 
this therapy is effective in a mouse model of spontaneous mela-
noma, reinforcing the potential pathophysiological relevance 
of our findings. The data offer novel mechanistic insights into 
the role and function of tumor-reactive CD4+ T cells, and have 
significant clinical relevance for ACT, including approaches 
incorporating gene therapy. Collectively, they suggest that a 
small number of naive T cells transduced to express tumor-
  reactive TCRs might be sufficient to drive tumor rejection   
after differentiation in vivo, offering an alternative to the ex-
tensive ex vivo manipulation that is required to achieve high 
numbers of in vitro–differentiated tumor-reactive T cells.
The data demonstrate that RT in combination with 
CD4+Trp1+ transfer results in expansion, intratumor accu-
mulation, and differentiation of the transferred cells into 
IFN-–, TNF-, IL-2–, and granzyme B–producing effector 
cells, whereas RT or CD4+Trp1+ transfer alone fail to medi-
ate these changes (Figs. 1 and 2). Contrary to most studies of 
ACT using T cells activated in vitro, tumors continued to 
grow after CD4-ACT, and started to necrose and regress sev-
eral days thereafter (Fig. 1 b). This may reflect a requirement 
for  priming,  expansion  in  the  lymphopenic  environment, 
and differentiation of the transferred cells before acquisition 
Finally, it illustrates the potency of this therapy, as demonstrated 
by its ability to mediate regression of many tumor lesions   
developing for up to 4 mo at different sites in the mouse.
DISCUSSION
Adoptive transfer of high numbers of tumor-reactive lympho-
cytes into lymphoablated patients is a promising therapy for late 
metastatic disease, particularly metastatic melanoma (Dudley   
et al., 2002, 2008). Although initially focused on CD8+ CTL 
responses (Yee et al., 2002), recent preclinical and clinical studies 
have redirected attention to CD4+ T cells, which are thought 
to provide the necessary help to the effector CD8+ CTL com-
partment (Hunder et al., 2008). In this paper, we demonstrate 
that CD4+ T cells transferred into lymphopenic mice can me-
diate rejection of large vascularized melanoma tumors, particu-
larly when combined with CTLA-4 blockade. These data are 
significant for several reasons: (a) CD4-mediated rejection does 
not require expansion and manipulation in vitro, but occurs   
after activation and differentiation of small numbers of naive   
T cells in vivo in a lymphodepleted host; (b) tumor-reactive 
CD4+ T cells acquire cytotoxic activity and directly reject the 
tumor in an MHC class II–dependent manner; and (c) CTLA-
4 blockade greatly enhances therapeutic efficacy of CD4-ACT, 
Figure 6.  B16 melanoma up-regulates class II expression in vivo in an IFN-–dependent manner and are direct targets of cytotoxic CD4+Trp1+ 
T cells. (a) In vivo class II expression by tumor cells from mice receiving either CD4+Trp1+ cells alone or in combination with 5 Gy of RT and in the presence or 
absence of blocking anti–CTLA-4 and neutralizing IFN-. Mice were treated at day 10 after challenge with B16/BL6 melanoma expressing Thy1.1 and sacri-
ficed 7 d after initiation of therapy (day 17 after tumor). Single-cell suspensions of tumors were analyzed for MHC class II levels by gating in Thy1.1-positive 
cells. Numbers indicate percentages. (b) Quantification of class II expression by tumors in vivo shown as cumulative data from three independent experiments 
(n = 3 mice per group). Horizontal bars represent means. (c) CD4+Trp1+ T cells were primed in vivo and expanded in vitro to allow analysis of their antitumor 
activity upon retransfer into tumor-bearing CII/ recipient mice. In brief, 10 d after tumor challenge, MHC CII/ recipient mice were treated with 5 Gy of RT, 
primed CD4+Tpr1+ cells, and anti–CTLA-4. Half of the mice were also treated with 200 µg of blocking anti–class II antibody every 3 d, and tumor growth was 
monitored over time. Data are representative of two independent experiments (n = 5 mice per group). Error bars represent means ± SEM.646 Tumor rejection by cytotoxic CD4+ T cells | Quezada et al.
Importantly, in RAG-sufficient hosts, RT may also contrib-
ute by sensitizing the tumor stroma (Zhang et al., 2007) and 
by increasing the expression of adhesion molecules on the 
tumor vasculature, which would render the tumor suscepti-
ble to T cell infiltration (Ganss et al., 2002; Lugade et al., 
2005; Quezada et al., 2008).
Although  total  body  irradiation  has  been  successfully   
used in several major cancer centers across the United States 
(Muranski et al., 2006; Dudley et al., 2008), clinical applica-
tion of our findings may benefit from future studies address-
ing alternatives to lymphodepletion. If the main contribution 
of RT is to induce lymphopenia, then conditioning of recipi-
ents by lymphodepleting chemotherapy regimens should also 
of full antitumor activity. Although slower to manifest than 
the antitumor effect observed after ACT with cells expanded 
in vitro (Hanson et al., 2000; Overwijk et al., 2003; Spiotto 
et al., 2004; Antony et al., 2005), priming in vivo in the lym-
phopenic hosts is extremely efficient, resulting in rejection of 
large tumors of up to 600 mm3.
Transfer of CD4+Trp1+ cells into nonirradiated tumor-
bearing RAG/ mice, which lack B and T cells, also resulted 
in extensive proliferation, cytokine production, and tumor 
rejection (unpublished data), suggesting that the main role of 
RT in this model is the induction of lymphopenia and/or 
the  elimination  of  cytokine  sinks  limiting  tumor-reactive   
T cell responses (Gattinoni et al., 2005a; Muranski et al., 2006). 
Figure 7.  Triple therapy mediates tumor regression in a mouse model of spontaneous melanoma. Grm-1 Tg mice spontaneously develop mela-
noma tumors between 4–6 mo of age. After development of large tumor lesions (10–13 mo of age), mice were treated with 5 Gy of RT in combination 
with tumor-reactive CD4+Trp1+ T cells and anti–CTLA-4, as described in Materials and methods. Tumor progression was monitored weekly by gross mor-
phological examination. The individual tumor lesions were measured with calipers weekly for each animal. The total tumor volume for each mouse was 
considered as 100% on the first day of treatment. (a) Representative images of treated mice and tumor regression. (b) Tumor volume after triple therapy. 
(c) One mouse with aggressive disease continued to grow tumor up to day 10 after therapy when tumor volume started to decrease, similar to what is 
observed in the transplantable B16/BL6 model. (d and e) Mice were also monitored for expansion of CD4+Trp1+ T cells in the blood (d) and cytokine levels 
in the serum (e) of treated mice. Data are representative of two independent experiments (n = 7–10 mice).JEM VOL. 207, March 15, 2010 
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physiological model for self-/tumor antigen emphasizes the 
promise  of  these  cells  in  cancer  immunotherapy.  Further 
identification and induction of tumor-reactive CD4+ T cells 
with cytotoxic activities in cancer patients may offer signifi-
cant advantages for the treatment of human malignancies. 
These cells could be isolated and minimally expanded before 
reinfusion into conditioned recipients. The feasibility of such 
strategies is supported by the potent tumor rejection observed 
in CII/ mice after transfer of CD4+Trp1+ T cells that had 
been originally primed in vivo and then minimally expanded 
before transfer into lymphopenic tumor-bearing mice (Fig. 6 c).   
Furthermore, similar approaches for the isolation of tumor-
reactive lymphocytes after immunotherapy followed by au-
tologous  transfer  into  conditioned  recipients  have  been 
previously demonstrated in preclinical (Quezada et al., 2008) 
and clinical settings (Rapoport et al., 2005; June, 2007).
Other aspects of CD4+Trp1+ T cell function were equally 
critical for tumor eradication. The Th1-like phenotype that 
developed after transfer into a lymphopenic environment was 
characterized by the production of high levels of TNF, IL-2, 
and IFN-. IFN- was clearly required for tumor rejection 
and appeared to directly affect tumor cells in our model, be-
cause tumor regression was observed in IFN-R/ recipi-
ents. In addition, MHC II expression by tumor cells depended 
on IFN- because its neutralization prevented MHC II up-
regulation (Fig. 6, a and b). This is in keeping with previous 
work on autoimmunity demonstrating that IFN- secreted 
by CD4+ T cells can mediate up-regulation of class II on tar-
get cells (Wu et al., 1999, 2000). Remarkably, tumors recru-
desced in all IFN-R/ recipients after initial regression, 
suggesting that an IFN-–sensitive cell type other than the 
tumor may have a role in mediating long-term protection, in 
accordance with previous observations using CD8-ACT in 
which rejection of the tumor stroma was critical for complete 
tumor eradication (Spiotto et al., 2004; Zhang et al., 2007).
Based on these data, we propose a model in which   
tumor-reactive CD4+Trp1+ T cells transferred into lympho-
penic mice expand, differentiate into IFN-–secreting, cyto-
toxic CD4+ cells, and accumulate within the tumor. IFN- 
induces up-regulation of MHC II on tumor cells, rendering 
them targets for the killer activity of CD4+Trp1+ cells. Finally, 
cytotoxic activity depends absolutely on class II expression by 
the tumor and correlates with high levels of granzyme B 
within CD4+Trp1+ cells in LNs and particularly in tumors, 
where it is expressed by 40–50% of infiltrating CD4+Trp1+ T 
cells (Figs. S1 and S2). As part of a more global view and in 
addition to their direct impact on the tumor, IFN-–secreting 
CD4+Trp1+ cells may also induce a cascade of events involv-
ing priming of cytolytic CD8+ T cells through activation of 
DCs and additional tumor destruction through activation of 
NK cells. Furthermore, high levels of IFN- in the tumor 
may also lead to activation of type I macrophages, which will 
also favorably affect antitumor activity.
In conclusion, we believe that these data greatly inform our 
basic understanding of the importance of tumor-reactive CD4+ 
T cells in the context of ACT. Equally importantly, they support 
create an environment favorable to tumor rejection by adop-
tive transfer of small numbers of tumor-reactive CD4+ T 
cells. Finally, lymphodepletion may not be the only way to 
fully activate tumor-reactive CD4+ T cells; thus, alternatives 
including activation of the APC compartment (i.e., CD40 
and TLR agonists) should be addressed in future studies.
The addition of CTLA-4 blockade to RT and CD4+Trp1+ 
transfer  further  enhanced  antitumor  responses,  inducing 
higher total numbers of CD4+Trp1+ cells and higher levels of 
TNF and IFN- in serum samples (Fig. 1). CTLA-4 block-
ade did not modify cytokine production on a per cell basis 
but increased the number of tumor-reactive cells, accounting 
for the overall increase in levels of inflammatory cytokines in 
the serum. Equally important, CTLA-4 blockade resulted in a   
significant reduction in the absolute number of CD4+Trp1+ 
Foxp3+ and endogenous T reg cells in the periphery and in 
the tumors. Collectively, these changes may create a state of 
combined hyperactivation and reduced regulation, correlating 
with increased cytotoxicity (Fig. 5 a) and resulting in com-
plete tumor rejection. Notably, restricting CTLA-4 blockade 
to the transferred cells was sufficient to induce maximal anti-
tumor activity, suggesting a strategy for future combinatorial 
approaches incorporating TCR transfer and CTLA-4 abla-
tion on the same cell, which may avoid adverse immune 
events associated with systemic administration of anti–CTLA-4 
antibodies (Peggs et al., 2006).
Although previous studies have indicated that Th17 cells 
polarized in vitro are capable of inducing tumor rejection 
(Muranski et al., 2008), we did not observe differentiation 
of CD4+Trp1+ cells into IL-17 producers in vivo (unpub-
lished data). In the previous study, tumor rejection was   
dependent mostly on IFN- despite the requirement for 
differentiation into Th17 cells, in accordance with studies 
suggesting a possible reversion of Th17 into Th1 cells (Shi 
et al., 2008; Lee et al., 2009; Martin-Orozco et al., 2009). 
In  contrast,  we  believe  that  priming  of  tumor-reactive 
CD4+Trp1+ T cells in vivo in a lymphopenic environment 
leads directly to a Th1-like phenotype. Surprisingly, these 
cells also expressed high levels of granzyme B in the periph-
ery and tumors (Figs. S1 and S2), which correlated with ac-
quisition of granzyme-dependent cytotoxic activity (Fig. 5) 
and potent rejection of large established tumors.
The acquisition of cytotoxic activity by transferred tu-
mor-reactive CD4+ T cells is particularly striking. This dis-
tinguishes  our  findings  from  previous  work  showing  that 
CD4+ T cells can help rejection of less well-established tu-
mors through indirect effects of IFN- (Mumberg et al., 
1999) on NK cells (Perez-Diez et al., 2007) and tumor-infil-
trating macrophages (Greenberg et al., 1985; Hung et al., 
1998; Corthay et al., 2005; Corthay, 2007). Interestingly, 
CD4+Trp1+ cells developed all the hallmarks of CD4+ Th 
cells with the additional benefit of exhibiting cytolytic activity. 
CD4+ CTLs targeting viral antigens (Paludan et al., 2002; Hegde 
et al., 2005; Heller et al., 2006) and alloantigens (Holloway 
et al., 2005; Spaapen et al., 2008) have been described previ-
ously, but the demonstration of similar activity in a more 648 Tumor rejection by cytotoxic CD4+ T cells | Quezada et al.
and permeabilized (eBioscience) according to the manufacturer’s instructions, 
and stained with anti-Foxp3–PE (FJK-16s). Flow cytometry reference beads 
(PeakFlow blue; Invitrogen) were mixed with the samples before analysis to 
normalize for the volume of the sample acquired. The absolute number of 
CD4+Trp1+ cells per tumor was calculated using the following formula: 
number of CD4+Trp1+ cells = (count of CD4+Trp1+ cells/count of beads)/
tumor weight. For functional analysis, restimulated samples were stained as 
described, fixed, and permeabilized using Cytofix/Cytoperm (BD), followed 
by anti–IFN-–Alexa Fluor 488 (XMG1.2), anti-TNF–PE (MP6-XT22) or 
anti–IL-2–PE (JES6-5H4), and anti–granzyme B–allophycocyanin (GB11).
Immunofluorescence. Tumors were flash frozen in optimal cutting tem-
perature solution (Sakura). 10-µm sections were cut with a microcryotome 
(Leica), fixed for 10 min in cold acetone, and stained with anti-CD4–Alexa 
Fluor 488, anti-CD31–PE, and DAPI, and analyzed on an inverted confocal 
microscope (LSM; Leica) under a 20× water immersion objective.
Blood cytokine measurements. Serum from blood samples was analyzed 
using a Mouse Inflammation Cytometry Bead Array (BD) according to the 
manufacturer’s instructions.
In vivo cytotoxicity. Splenocytes from B6.SJL mice were labeled with 5 
or 0.5 µM CFSE. CFSEhigh splenocytes were loaded with 20 µM of Trp1 
peptide (Bio-Synthesis) for 2 h at 37°C. On day 17 after tumor challenge   
(7 d after CD4+Trp1+ transfer), 5 × 105 cells of a 50:50 mixture of Trp1 
peptide–loaded and –unloaded splenocytes were transferred by tail vein   
injection. 14–16 h later, mice were sacrificed and spleens and LNs were   
removed, and the percentage of loaded and unloaded B220+ splenocytes was 
analyzed. Cytotoxicity was calculated using the following formula: cytotox-
icity = 100% × (1((unloaded/loaded)control/(unloaded/loaded)experimental)).
Trp1 in vitro expansion and in vitro cytotoxicity. 7 d after adoptive 
transfer into irradiated tumor-bearing mice, CD4+Trp1+ cells were purified 
from LNs using CD4 beads (Miltenyi Biotec) and cultured with equal num-
bers of DCs and 2 µM of Trp1 peptide. After 3 d, cell cultures were supple-
mented with DCs, 30 U/ml IL-2, and 2 µM of Trp1 peptide. After 3 d, cells 
were harvested and used for in vitro cytotoxicity assays or for transfer into 
tumor-bearing CII/ recipients. To determine in vitro killing of tumor targets, 
B16/BL6 tumor cells were loaded with 0.5 mM CFSE, whereas EL-4 control 
cells were loaded with 5 mM CFSE. Fluorescent reference beads were mixed 
with the samples before analysis to normalize for the volume of the sample 
acquired. Blocking anti–I-Ab and anti-FASL (MFL4 clone) mAbs were used 
at a final concentration of 50 µg/ml, whereas concanamycin A (Sigma-
  Aldrich) and the granzyme B inhibitor Z-AAD-CMK (Enzo Biochem, Inc.) 
were used at 0.5 and 25 µM, respectively.
Statistical analyses. Data were analyzed using Prism 5.0 (GraphPad Software, 
Inc.). Experiments were repeated two to three times. Statistical significance 
was determined by a Student’s t test (between two groups or conditions) or 
analysis of variance with a post-hoc test (three or more groups or conditions). 
Tumor survival data were analyzed with the Kaplan-Meier method. The 
log-rank test was used to compare survival curves for different subgroups on 
univariate analyses. P < 0.05 was considered statistically significant.
Online supplemental material. Figs. S1 and S2 show the levels of intra-
cellular cytokines (IFN-, TNF, and IL-2) and granzyme B produced by 
CD4+Trp1+ T cells isolated from LNs (Fig. S1) and tumors (Fig. S2) of mice 
receiving different treatments. Fig. S3 depicts histological analysis of whole 
tumors from mice treated with RT with or without CD4+Trp1+ T cells and 
anti–CTLA-4. Fig. S4 illustrates tumor infiltration by CD4+V14+ T cells 
after treatment with RT and CD4+Trp1+ T cells with and without anti–
CTLA-4.  Online  supplemental  material  is  available  at  http://www.jem 
.org/cgi/content/full/jem.20091918/DC1.
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development of clinical strategies focusing on exploiting the 
function of cytotoxic tumor-reactive CD4+ T cells generated 
after transfer and activation in vivo, which may obviate re-
quirements for extensive and possibly detrimental manipula-
tion in vitro before adoptive transfer. Finally, the augmented 
potency  of  the  transferred  tumor-specific  T  cells  observed 
upon blockade of coinhibitory molecules such as CTLA-4 
provides a basis for the improvement of ongoing ACT trials as 
well as for the development of future combinatorial trials.
MATERIALS AND METHODS
Mice. 6–8-wk-old C57BL/6, B6.SJL, RAG2/, Prf/, IFN-/, IFN-
R/, and MHC CII/ 78 mice were purchased from the Jackson Labo-
ratory.  Trp1  Tg  mice  carry  TCR    and    transgenes  on  a  background 
homozygous for the targeted mutation Rag1tm1Mom and homozygous for the 
white-based brown radiation–induced mutation of Trp1, Tyrp1B-w (Muranski 
et al., 2008). These mutant mice express an MHC class II–restricted (I-Ab) 
TCR recognizing the endogenous melanocyte differentiation antigen–minimal 
TRP-1 epitope corresponding to amino acids 113–127. Trp1 Tg mice were 
crossed  to  B6.SJL  mice,  and  their  progeny  were  intercrossed  to  generate 
CD45.1+/+Trp1 Tg mice (also on the Tyrp1B-WRAG/ background). Grm-1 
Tg mice (Pollock et al., 2003) were provided by S. Chen (Rutgers, The State 
University of New Jersey, Piscataway, NJ). Grm-1 Tg mice overexpress the 
metabotropic Grm-1 driven by the melanocyte-specific promoter of dopach-
rome tautomerase. Mice develop spontaneous melanoma lesions primarily in 
the tail and pinnae of the ear between 4 and 6 mo of age. Mice were housed 
in specific pathogen-free conditions in accordance with institutional guide-
lines. All animal experiments were approved by the Memorial Sloan-Kettering 
Cancer Center Institutional Animal Care and Use Committee.
Cell  lines.  The  poorly  immunogenic  B16/BL6  cell  line  was  originally   
obtained from I.J. Fidler (M.D. Anderson Cancer Center, Houston, TX). 
The lymphoma EL-4 was obtained from the American Type Culture Col-
lection. B16/BL6 cells were transduced and selected to constitutively express 
either Thy1.1 or Renilla luciferase.
Antibodies. Anti–CTLA-4 (9H10), anti-NK1.1 (PK136), anti-CD8 (2.43), 
anti–IFN- (XMG1.2), anti-TNF (XT3.11), and anti–I-Ab (M5/114) were 
purchased from BioXCell and administered i.p. Antibodies for flow cytom-
etry and immunofluorescence were purchased from eBioscience and BD.
Tumor challenge and treatments. Mice were challenged intradermally 
(i.d.) with 2.5 × 105 B16/BL6 tumor cells on day 0. In some experiments, 
mice received an additional i.d. challenge of 2.5–5 × 105 EL-4 lymphoma 
cells on the opposite flank, or a mix of both tumors in one unique site. On 
day 10, mice were treated or not with 5 Gy of total body irradiation, 50,000 
CD4+Trp1+ cells i.v., and 200 µg anti–CTLA-4 i.p. Mice received addi-
tional anti–CTLA-4 injections of 100 µg on days 13, 16, 20, and 24. For 
neutralization and blocking experiments, 200 µg anti–IFN-, anti-TNF, or 
anti–I-Ab was administered 1 d before initiation of therapy and every 2 d   
after that for a total of six injections. CD4+Trp1+ for adoptive transfers was 
isolated from Trp1 Tg mice using CD4 magnetic beads (Miltenyi Biotec).
Phenotypic and functional analyses. Mice used for functional experi-
ments were sacrificed on day 18 after tumor implantation, and LN cells and 
tumor-infiltrating  lymphocytes  were  isolated  as  previously  described 
(Quezada et al., 2006, 2008). Tumor-infiltrating CD4+ T cells were purified 
using  CD4  positive  selection  (FlowComp;  Invitrogen)  according  to  the 
manufacturer’s instructions. Purified CD4+ T cells from tumors or bulk cells 
from LNs were restimulated for 2 h at 37°C with 5 × 104 DCs and 2 µM of 
Trp1 peptide followed by addition of brefeldin A (BD) for 2 more hours.
Flow cytometry and quantification. Samples were stained with anti-
CD45.1–Pacific Blue (A20) and anti-CD4–PerCP-Cy5.5 (GK1.5), fixed, JEM VOL. 207, March 15, 2010 
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